SELLAS Life Sciences Stock Soars 156% on Positive Phase 3 Trial Data for Cancer Vaccine
The REGAL trial showed a 41% reduction in risk of death for patients with acute myeloid leukemia treated with galinpepimut-S, and the company plans to meet the FDA about a filing.

Key points
- SELLAS (SLS) rose 156.4% on Tuesday after positive Phase 3 REGAL trial results for its cancer vaccine GPS
- GPS cut the risk of death 41% in acute myeloid leukemia, with median overall survival of 24.0 vs 14.7 months
- The company plans to meet the FDA and prepare a BLA submission in the first half of 2027
- Cash and equivalents were $134.7 million as of Sept. 30, 2026
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) shot up 156.4% on Tuesday, Nov. 17, 2026, closing at $19.15 after its previous close of $7.47, after the company announced positive topline results from its pivotal Phase 3 REGAL trial. The S&P 500 ETF (SPY) fell 1.01% over the same session. Trading volume ran at about 19.1 times its usual level.
The news came in an 8-K filed before the market open, with the press release attached as Exhibit 99.1. The filing said the trial evaluated galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, as maintenance therapy in patients with acute myeloid leukemia who were ineligible for or unable to undergo allogeneic stem cell transplantation.
GPS met its overall survival endpoint
REGAL met its primary endpoint of overall survival. GPS showed a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. Median overall survival was 24.0 months for GPS-treated patients, compared with 14.7 months for those receiving best available treatment.
The company said GPS was generally well tolerated, with no new safety signals. Treatment-related adverse events were mostly mild to moderate, most commonly local injection site reactions.
Next steps point to a filing in 2027
SELLAS said it plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy and to advance preparations for a Biologics License Application for GPS in the first half of 2027. Full secondary endpoint analyses are underway and will be presented at an upcoming medical conference and submitted for publication.
Cash and losses before the news
SELLAS reported cash and equivalents of $134.7 million as of Sept. 30, 2026. Its net loss for the latest reported quarter was $10.1 million, compared with $6.8 million a year earlier, and its diluted loss per share was $0.05 against $0.06.
Sources
Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.
Other stock movers this week
- Woodward Stock Rises 5% After Record Fiscal 2026 Results and Strong Fourth Quarter · WWD · Nov. 19, 2026
- J&J Snack Foods Stock Jumps 9.5% on Fiscal Q4 Results and Cost Savings Update · JJSF · Nov. 18, 2026
- Valvoline Stock Rises 10% as Fourth-Quarter Results Are Released · VVV · Nov. 19, 2026
- ACI Worldwide Stock Falls 10% as CEO Thomas Warsop Resigns and CFO Takes Interim Role · ACIW · Nov. 18, 2026
More on SELLAS Life Sciences Group
SLS page →Filings, figures and price history are on the SELLAS Life Sciences Group page.